AdipoSeeds finished raising 4 million yen through CHUGAI PHARMACEUTICAL and investment funds that Keio Innovation Initiative (KII), Kanagawa Science Park (KSP) and DOGAN operate each. AdipoSeeds, Inc. was established in July 2016 to develop a regenerative medicine derived from ASCL-derived Platelet Like Cells (ASCL-PLC) based on the novel research result by Yumiko Matsubara, associate professor at the Clinical and Translational Research Center, School of Medicine, Keio University. AdipoSeeds’ corporate mission is “Making Platelets from Fat Tissue and Inventing New Blood Supply System” through developing a regenerative medicine based on a proprietary technology of (1) establishing Adipose-derived Mesenchymal Stem/stromal Cell Line (ASCL) by refining Adipose-derived Mesenchymal Stem/stromal Cell (ASC) which is extracted from human subcutaneous fat tissue, (2) differentiating and deriving ASCL-derived Platelet Like Cells (ASCL-PLC) from ASCL. We focus on contributing to solve the deficiency of platelets which becomes remarkable in the future all over the world and create the future in which medical treatment in conjunction with safe platelets at low cost. AdipoSeeds plans to use the raised fund to promote the clinical study of ASCL-PLC for the treatment of Intractable Cutaneous Ulcer in collaboration with Scholl of Medicine of Keio University.